Posted 05 April, 2023
Acasti Pharma Inc. appointed Prashant Kohli as new CEO
Nasdaq:ACST appointed new Chief Executive Officer Prashant Kohli in a 8-K filed on 05 April, 2023.
On April 4, 2023, Acasti Pharma Inc. (the "Company") announced it has appointed Prashant Kohli as the Company's Chief Executive Officer, succeeding Jan D'Alvise, who has mutually agreed with the Company to depart.
Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Acasti Pharma Inc.
Health Care/Life Sciences • Pharmaceuticals
Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.Market Cap
$32.3M
View Company Details
$32.3M
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 4, 2023, Acasti Pharma Inc. (the "Company") announced it has appointed Prashant Kohli as the Company's Chief Executive Officer, succeeding Jan D'Alvise, who has mutually agreed with the Company to depart. Ms. D'Alvise will also be stepping down from the Company's board of directors. Mr. Kohli, aged 51, served as the Company's Chief Commercial Officer since September 2022, where he was responsible for developing commercialization strategy and go to market plans for the Company's drug candidate pipeline, and was the Company's VP, Commercial Operations since August 2021. Prior to that, Mr. Kohli was VP Commercial Operations at Grace Therapeutics Inc. (which was acquired by the Company in August 2021) since December 2017. Mr. Kohli has also held a variety of commercial, corporate, and business development roles at Archi-Tech Systems Inc., Cardinal Health, Inc., IQVIA, Rosenbluth International Inc. and Dun & Bradstreet Corporation. He has a BA in Computer Science from Augustana College and an MBA from The Wharton School of Business. There are no transactions between Mr. Kohli or any member of his immediate family and the Company, or any of its subsidiaries, that would be reportable as a related party transaction under the rules of the Securities and Exchange Commission. In addition, there are no family relationships between Mr. Kohli and any current director or executive officer of the Company. The Company will file an amendment to this Form 8-K disclosing the compensation arrangements for Mr. Kohli's service as Chief Executive Officer, once available. In connection with her departure, Ms. D'Alvise will will receive the separation benefits payable in accordance with the terms of her employment agreement.
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.